Al Sandrock, Voyager Therapeutics CEO

Al San­drock prunes his post-Bio­gen voy­age with sim­i­lar fo­cus on ALS

Al San­drock is nar­row­ing the fo­cus of Voy­ager Ther­a­peu­tics, con­cen­trat­ing on CNS dis­eases that were the hall­mark of his time lead­ing R&D at Bio­gen, in­clud­ing an em­pha­sis on a fa­mil­ial form of ALS for which his for­mer em­ploy­er is get­ting a speedy re­view at the FDA.

Less than six months in­to his jour­ney as CEO at Voy­ager, San­drock is fo­cus­ing the pre­clin­i­cal pipeline on Alzheimer’s dis­ease, GBA1 Parkin­son’s dis­ease and SOD1 amy­otroph­ic lat­er­al scle­ro­sis, the rare form of ALS for which the FDA will de­cide whether to ap­prove Bio­gen’s tofersen by Jan. 25, 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.